Promising Data On Head And Neck Cancer Announced By DNAR At 2008 American Society Of Clinical Oncology Meeting
The DNA Repair Company (DNAR), an emerging company focused on personalized approaches to cancer treatment, today announced promising early clinical data for identifying effective treatment regimens for head and neck cancer. An analysis of DNA repair protein biomarkers was performed in collaboration with the University of Chicago Medical Center that identified biomarker combinations as novel predictors of response to treatment with induction chemotherapy and overall survival.
Seattle Genetics Reports Multiple Complete And Partial Responses With SGN-35 In Patients With Lymphoma
Seattle Genetics, Inc. (Nasdaq: SGEN) announced positive data from a phase I clinical trial of SGN-35, an antibody-drug conjugate (ADC), demonstrating multiple objective responses at well-tolerated doses in patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies.
Laser Technique Fights Cancer With Light
When Sammie Bush mentioned to his doctor that he sometimes felt something in the back of his throat, he didn't expect to learn that he had cancer or that he would be the first patient at the University of Illinois Medical Center at Chicago to undergo photodynamic therapy -- a new procedure that uses light to destroy cancer.
Semafore Pharmaceuticals Reports Positive Interim Results From A Phase I Study Of SF1126, A Targeted Pan-PI3K Inhibitor
Semafore Pharmaceuticals Inc. reported interim data from a Phase I study of its lead product candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be evaluated clinically in both solid tumor and multiple myeloma trials.
FDA Investigating Arthritis Drugs And Cancer Risk In Children
The US Food and Drug Administration (FDA) is investigating a possible link between tumor necrosis factor (TNF) blockers, a class of drugs for treating arthritis and other conditions, and cancer risk in children.In an early communication issued yesterday, 4th June, the FDA's Center for Drug Evaluation and Research (CDER) said it was investigating the possible link between TNF blockers and the development of lymphoma and other cancers in children and young adults.
Link Between Inflammation, Cancer Confirmed By MIT
Chronic inflammation of the intestine or stomach can damage DNA, increasing the risk of cancer, MIT scientists have confirmed.The researchers published evidence of the long-suspected link in the June 2 online issue of the Journal of Clinical Investigation (JCI).
Prognosis For Colorectal Cancer Patients Improved If Family Members Have Had Disease
According to a paper published in the June 4 issue of JAMA, patientswith advanced colon cancer who receive chemotherapy and who have afamily history of colorectal cancer have a significantly lowerlikelihood of cancer recurrence and death. Jennifer A. Chan, M.
Delcath Expands Phase III Trial For Metastatic Melanoma To Include St. Luke's Cancer Center
Delcath Systems, Inc. (Nasdaq: DCTH) announced that the St. Luke's Cancer Center of Bethlehem, PA, part of St. Luke's Hospital & Health Network (St. Luke's), has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan.
Bavarian Nordic Enters Clinical Trials With Prostate Cancer Vaccine
Bavarian Nordic's subsidiary, BN ImmunoTherapeutics has initiated PhaseI/II clinical studies with its therapeutic vaccine candidate against prostatecancer. A Phase I/II safety and tolerability study in 18 male patients withnon-metastatic as well as hormone-insensitive prostate cancer has begunenrolment in the US.
ADVENTRX Presents CoFactor Data At The 2008 Annual Meeting Of The American Society Of Clinical Oncology ASCO
ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFactor(R), for the treatment of advanced breast cancer at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which takes place May 30 - June 3, 2008 in Chicago, IL.